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Abstract
Background:  Infection with the filarial nematode Onchocerca volvulus can lead to severe dermatitis, visual
impairment, and ultimately blindness. Since the currently used drug, ivermectin does not have macrofilaricidal or
strong permanent sterilising effects on the adult worm, more effective drugs are needed to complement the use
of ivermectin alone. Wolbachia endosymbiotic bacteria in filariae have emerged as a new target for treatment with
antibiotics which can lead to long -term sterilization of the adult female filariae.
Methods: In the Central Region of Ghana, 60 patients were recruited, allocated into four groups and treated
with 200 mg doxycycline per day for 2 weeks, 4 weeks, 6 weeks respectively. Untreated patients served as
controls. Some of the treated patients and the untreated controls were given 150 µg/kg ivermectin 8 months after
the start of doxycycline treatment.
Results: A follow up study 18 months post treatment showed that when using doxycycline alone there was a
significant reduction of microfilarial (mf) loads in patients treated for either 4 or 6 weeks. However, there was
no significant difference between the untreated controls and those given the 2 weeks regimen. Although no
significant difference was demonstrated between the 4 and 6 weeks regimens, there was a trend observed, in that,
microfilarial reduction appeared to have been greater following the 6 weeks regimen. Twelve months after
ivermectin (i.e. 20 months after doxycycline) treatment, 8 out of 11 ivermectin-alone treated patients were mf-
positive. In contrast, 1 out of the 7 patients treated for 4 weeks with doxycycline and none of the 4 patients
treated for 6 weeks doxycycline (who were available for re-examination) were mf-positive after the combined
treatment of doxycycline plus ivermectin treatment.
Conclusion: Treatment of onchocerciasis with doxycycline for 4 weeks is effective. Nonetheless, mf reduction
appeared to be greater in the 6 weeks regimen. It is recommended that until further studies are carried out i.e.
4 weeks treatment with doxycycline is proven equivalent to the 6 weeks, selected groups of onchocerciasis
patients should be treated for 6 weeks with doxycycline. As discussed earlier, this treatment should be
accompanied by two doses of ivermectin.
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Background
Onchocerciasis, commonly known as river blindness, is
caused by the filarial nematode, Onchocerca volvulus [1]. It
is an important cause of visual impairment and dermati-
tis, affecting about 18 million residents in Africa and Latin
America [2]. The infection is known to be endemic in 37
countries [2]. In 1995, the World Health Organization
Expert Committee on Onchocerciasis estimated that 123
million people were at risk of contracting the infection,
and about 18 million were infected of whom 270, 000
were blind and 500, 000 severely visually impaired [3]. A
recent study has shown a direct association between
microfilarial load and excess mortality in onchocerciasis
patients [4].
The world community aims to eliminate onchocerciasis as
a public health problem [5]. Since the close down of the
Onchocerciasis Control Programme (OCP) in West Africa
at the end of 2002, all subsequent onchocerciasis control
was transferred to the participating countries [6], and it is
almost entirely based on periodic mass treatment with
ivermectin using community directed treatment with iver-
mectin (CDTI) as in the African Programme for
Onchocerciasis Control (APOC) [7]. APOC relies on com-
munity-based mass distribution of ivermectin once a year.
It is accepted that APOC in its current form might not stop
transmission completely [8,9]. The crucial problem is that
ivermectin leads to depletion of skin microfilariae (mf)
for only a few months, followed by reappearance of mf
within one year at levels of more than 20% of that at pre-
treatment [10-12] and this mf (microfilaria) density
seems sufficient for transmission to continue.
In order to achieve elimination of onchocerciasis as a pub-
lic health problem, ivermectin has to be applied annually
for 10 - 20 years or more [3,5,13]. This is due to the lon-
gevity of adult worms, which can live for 9 - 14 years [14]
and are not killed by ivermectin. Ivermectin given at
shorter intervals of three- or six-months, rather, than the
standard annual treatment may lead to excess mortality in
the adult stages of O. volvulus [15-18]. However, more
recent meta-analysis of extensive data from former OCP
areas has shown that even semi-annual mass treatment of
ivermectin for several years, followed by cessation e.g. due
to political unrest, has resulted in high rates of recrudes-
cence [6]. Ivermectin does not strongly affect early embry-
ogenesis [19], with the results indicating that there is not
a permanent sterilising effect. Indeed, microfilariae (mf)
continue to be released and re-emerge in the skin of
treated onchocerciasis patients several months after treat-
ment. A review of the impact of 10 - 12 years of ivermectin
treatment revealed that ivermectin was very effective in
controlling the public health aspect of the disease. How-
ever, elimination of transmission proved difficult [6]. It is,
therefore, unlikely that the scheme of ivermectin used cur-
rently can provide a complete solution to onchocerciasis.
A recent conference on the eradicability of onchocerciasis
concluded that eradication is not feasible with the present
tools alone [13]. In addition, sub-optimal efficacy of iver-
mectin and/or ivermectin resistance in humans has been
reported in onchocerciasis patients in Ghana where
despite multiple treatments with ivermectin, microfilari-
dermia persisted in some patients [20,21]. It is important,
therefore, to continue the development of alternative
drugs for the treatment of onchocerciasis. Particularly use-
ful would be a drug which kills or permanently sterilises
the adult worms, thus ensuring a more definite impact of
control on the reservoir of the parasite and possibly
achieving finally its eradication [5]. There is, therefore, a
pressing need for new antifilarial drugs which have mac-
rofilaricidal efficacy, or which show total and long-lasting
suppression of embryogenesis, in order to complement
microfilaricides such as ivermectin [5].
Members of the tetracycline group of antibiotics have
recently been proven to have antifilarial effects in animals
[22,23] and in humans [24,25]. Their action is based on
the targeting of Wolbachia  endobacteria which exist in
most filarial species [26].
A first study carried out on the effects of doxycycline treat-
ment in onchocerciasis patients suggests that treatment
with 100 mg per day for six weeks is effective in sterilising
the female adult worms [25,27]. However, further investi-
gations are needed to find out if shorter treatment regi-
mens with a higher dose of 200 mg per day would be
equally effective. Therefore, in the present study, we ana-
lysed the mf loads for up to 18 months after the beginning
of doxycycline treatment in patients treated either with
doxycycline alone using different treatment regimens,
with ivermectin alone, or with doxycycline plus ivermec-
tin.
Methods
Study site and patient recruitment
The study was carried out in 3 selected villages namely
Akropong, Buabinso, and Denkyira Fosu, all in the Upper
Denkyira District in the Central Region of Ghana, along
the Offin river which is an endemic area for onchocercia-
sis [27]. It is a forest zone outside the Onchocerciasis Con-
trol Programme (OCP) area. The community prevalence
of onchocerciasis in the study villages were 70%, 83% and
82% for Akropong, Buabinso, and Denkyira Fosu respec-
tively (RD Horstmann et. al., unpublished data). The
Table 1: Microfilariae/skin snip of patients selected for the study
Mf/skin snip 5–10 11–20 21–50 Above 50 Total
Number of patients 3 12 29 43 87Filaria Journal 2006, 5:1 http://www.filariajournal.com/content/5/1/1
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study was carried out from January 2000 to December
2002. Community mass anti-filarial treatment with iver-
mectin had started in March 1999 in the district by the
Ministry of Health, but the district health administration
could not give us the treatment coverage for the study vil-
lages.
The study design was approved by both the Ethical Com-
mittees of the School of Medical Sciences of the Kwame
Nkrumah University of Science and Technology, Kumasi,
and the Medical Board Hamburg, Germany. The study
procedure and the symptoms of the potential side effects
of doxycycline were explained to the participants. The
patients were asked to report any side effects experienced
in the course of the treatment period. Verbal consent was
given by each participant. All those taking part in the
study were informed that they could drop out of the study
at any time they wanted.
Figure 1
No. of patients recruited for
doxycycline only treatment
(n = 47)
Treatment allocation
Controls (no doxycycline)
(n = 16)
6 weeks doxycycline
(n = 15)
No. of drop out(s) = 0
Absent at 18 months (n = 2)
Patients available at 18 months
post therapy
(n = 14)
Patients available at 18 months post 
therapy
(n = 3)
No. of drop out(s)  after 2 weeks = 10
Absent at 18 months (n = 2)
2 weeks doxycycline treated
patients available at 18 months
post therapy
(n = 8)
4 weeks doxycycline
(n = 16)
No. of drop out(s)  after 2 weeks =2
Absent at 18 months (n = 1)
Patients available at 18 months post 
therapy
(n = 13)Filaria Journal 2006, 5:1 http://www.filariajournal.com/content/5/1/1
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Study exclusion and inclusion criteria
Volunteer onchocerciasis patients aged 18–50 years were
examined for palpable nodules and other chronic mani-
festations of onchocerciasis. Skin biopsies were taken
from patients with nodules and their mf were counted, in
order to enrol 87 patients for the study. Inclusion criteria
were as follows: Volunteer onchocerciasis patients aged
18–50 years, who were in good general health conditions,
and had a mf density of 5 mf or more per skin snip (Table
1). Exclusion criteria for the study were: abnormal hepatic
and renal profiles (alkaline phosphatase >200 U/l, gluta-
mate pyruvate transaminase >50 U/l, gamma glutamyl
transpeptidase >28 U/l and creatinine >1.2 mg/100 µl)
(measured by stick-chemistry) (Reflotron®, Roche Diag-
notics, Mannheim, Germany), regular intake of other
drugs, known mental illness, or other acute or chronic dis-
eases. Women were not selected for doxycycline treatment
but were included as control patients and offered ivermec-
tin treatment and nodulectomy.
Microfilarial count before therapy
Corneoscleral punches (Holth and modified Walser) were
used to take bloodless skin biopsies in the study and this
yielded skin snip weights of approximately 1.5 - 5.0 mg.
Two skin biopsies, one from the upper part of each but-
tock were taken from each patient before treatment.
Each skin biopsy was immersed in 100 µl of 0.9% NaCl
solution in a separate well of a 96-well round bottom
microtitre plate (Nunc, Roskilde, Denmark) and labelled
with the participant's code number. The wells of the plates
were then covered with adhesive tape to prevent evapora-
tion and spilling of the contents during transport to the
laboratory at the district hospital in Dunkwa. The skin
biopsies in the plates were incubated overnight at room
temperature to allow the emergence of the mf into the
saline solution. The solution in each well was thoroughly
mixed and pipetted onto a glass slide for microscopic
examination. Microfilariae were then counted using 63-
fold magnification of a microscope. Each skin biopsy,
after blotting to remove excess moisture, was weighed
Figure 2
No. of patients recruited for doxycycline
plus ivermectin treatment
(n = 40)
Treatment allocation
Control patients
(n=14)
Patients treated with 6 weeks doxycycline
(n = 13)
Patients available for snipping and
ivermectin treatment at 8 months post 
doxycycline therapy
(n =12 )
Patients available at 2 months post 
ivermectin therapy for snipping 
(n = 11)
Patients available at 2 months post 
ivermectin therapy for snipping
(n = 4)
Patients treated with 4 weeks doxycycline
(n = 13)
Patients available at 2 months post 
ivermectin therapy for snipping
(n = 7)
Patients available at 12 months
post ivermectin treatment  for snipping 
(n = 11)
Patients available at 12 months
post ivermectin treatment for snipping 
(n = 7)
Patients available at 12 months
post ivermectin treatment for snipping 
(n = 4)
Total no. of drop out(s) or absent at 12 
months post ivermectin therapy
( n = 3)
Total no. of drop out(s) or absent at 12 
months post ivermectin therapy  = 9
(n = 9)
Total no. of drop out(s) or absent at 12 
months post ivermectin therapy
(n = 6)
Patients available for snipping and
ivermectin treatment at 8 months post 
doxycycline therapy
(n =10 )
Patients available for snipping and
ivermectin treatment at 8 months post 
doxycycline therapy
(n = 10)Filaria Journal 2006, 5:1 http://www.filariajournal.com/content/5/1/1
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using a Sartorious electronic balance (Göttingen, Ger-
many), and the number of mf from each biopsy expressed
as the number of mf per milligram (mf/mg) of skin. The
geometric mean of the mf from the two skin biopsies from
each patient was calculated and used as a measure of
intensity of infection.
Doxycycline treatment
In all, 47 patients took part in the doxycycline-only
treated study. These patients were allocated to four groups
(Fig. 1) as indicated below and treated with doxycycline
(Vibramycin®, Pfizer) at a dose of 200 mg per day under
the direct observation of the team clinician who also
monitored participants for adverse reactions. Group 1: 12
patients received doxycycline for 2 weeks; group 2: 14
patients received doxycycline for 4 weeks; group 3: 5
patients received doxycycline for 6 weeks; and Group 4:
16 patients served as controls and received no doxycycline
treatment during the study period. Patients of group 1 had
been assigned to either group 2 or 3 but could either not
complete the full course or voluntarily dropped out of the
doxycycline administration. For instance, 10 patients in
group 1 had been assigned to group 3 (Fig. 1) but with-
drew after 2 weeks because they had to travel to their
hometown in another region for an emergency event,
whereas two patients assigned to group 2 voluntarily
withdrew from the doxycycline administration. They were
all followed-up during the study period.
Ivermectin treatment
Forty patients (Fig. 2) comprising of 14 untreated con-
trols, 13 patients from the 4 weeks doxycycline treated
regimen and 13 from the 6 weeks doxycycline treated reg-
imen were offered ivermectin 8 months after the start of
doxycycline treatment. Each patient received a single dose
of 150 µg/kg of ivermectin after snipping. Adverse reac-
tions to ivermectin were noted using a medical question-
naire by a clinician on the team.
Microfilarial count after therapy
Two skin biopsies, one from the upper part of each but-
tock were taken from doxycycline-only treated patients at
18 months after the start of doxycycline treatment, while
two skin biopsies were taken at 2 and 12 months after the
ivermectin administration from patients treated with iver-
mectin as has already been described above. Since iver-
mectin was administered 8 months after doxycycline
treatment, these two time points (2 and 12 months) cor-
responded to 10 and 20 months respectively after doxycy-
cline treatment.
Statistical analysis
Data were summarised as geometric means (GM). Micro-
filarial geometric mean intensities were calculated as anti-
log {(∑log(x+1))/n}-1, with x being the mean of mf/mg
of skin and n the number of individuals examined [25].
The efficacy of the various treatment regimens was
assessed comparing the proportion of mf-positive individ-
uals before and after treatment using Fisher's exact test.
Differences in GM of mf before and after treatment among
the various treatment regimens were analysed using
ANOVA multiple comparison Post Hoc test Bonferroni,
and differences within the same treatment groups were
assessed using Wilcoxon Signed Rank test. A result of p <
0.05 was considered significant. Independence of data
was tested using multivariate analysis (StatView®).
Results
Participation of patients at follow-up examinations
In all, 47 patients were recruited for the doxycycline-only
treated study but nine patients dropped out of the study
leaving 38 (Fig. 1). Of these nine patients, one died appar-
ently of strangulated inguinal hernia, another died of HIV
and seven individuals could not be re-examined because
they had moved from their villages. Forty patients were
also recruited for the doxycycline plus ivermectin study.
Eighteen dropped out or were absent at 12 months post
ivermectin therapy leaving 22 (Fig. 2).
Pre-treatment findings
The major treatment groups, the doxycycline-only-
treated, ivermectin-only-treated, doxycycline plus iver-
mectin-treated, and untreated controls were similar in
age, skin mf count, body weight and distribution of clini-
cal features. The most common skin lesions were atrophy
of the skin involving the lower half of the body and a
spotty depigmentation known as 'leopard skin'. Female
patients in the study had higher mf loads expressed as a
geometric mean (n = 15, GM = 17.1) than the males (n =
72, GM = 11.5). This difference was not significant using
the students t-test (P = 0.4093, Student's t-test).
Adverse reactions during and after treatment
The different treatment regimens with doxycycline were
all well tolerated in the study population with few and
only mild adverse reactions. Two patients experienced
transient diarrhoea and another person had diarrhoea
with bloody stool(s) for two days. No serious side effects
from doxycycline treatment were documented during the
treatment period. Adverse reactions such as itching, pruri-
tus, rash, fever, swellings, swollen lymph nodes, and
headache most directly associated with microfilarial kill-
ing occurred only after ivermectin administration. Symp-
toms of adverse reactions were noted using a medical
questionnaire by a clinician on the team.Filaria Journal 2006, 5:1 http://www.filariajournal.com/content/5/1/1
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Microfilarial counts recorded for doxycycline only 
treatment
Skin mf loads declined after treatment in all the treatment
regimens including the control patients (Table 2). How-
ever, very low mf counts were recorded as less than 1 mf/
mg for the 4 and 6 weeks groups compared to higher mf
loads in the 2 weeks and control groups 18 months after
treatment (Table 2).
Table 3 summarises the results of the relevant significance
tests comparing mf densities of the various treatment reg-
imens. In addition, the comparison of these observed dif-
ferences in the proportions of mf-positive people yielded
the following important results. Significant differences
were observed between controls and the 4 and 6 weeks
regimens (Table 4) but there were no significant differ-
ences between controls and 2 weeks regimen. This indi-
cates that treatment with doxycycline for 4 or 6 weeks
could be effective in treating onchocerciasis.
Microfilarial counts recorded for doxycycline plus 
ivermectin treatment
Ivermectin was administered to both doxycycline-treated
and untreated control patients 8 months after the start of
doxycycline treatment. The skin mf counts fell to zero 2
months after the administration of ivermectin in both
doxycycline-treated and untreated control patients
(Tables 5). However, mf re-appeared in 8 out of 11 iver-
mectin-only-treated patients within 12 months (Table 5)
after the ivermectin treatment. In contrast, the seven
patients treated with doxycycline for 4 weeks before iver-
mectin administration remained mf-negative with the
exception of one patient who had a very few mf at 12
months after treatment (Table 5). All the four patients
treated for 6 weeks with doxycycline, however, remained
mf-negative with none of the patients having mf in the
skin (Table 5). This suggests that 4–6 weeks doxycycline
plus ivermectin treatment is clearly more effective in
reducing and maintaining low microfilaridermia for 12
months than the use of ivermectin alone. There was a sig-
nificant difference between the ivermectin only treated
regimen and the doxycycline plus ivermectin regimens
(Table 6), but no difference between the 4 weeks doxycy-
cline plus ivermectin and the 6 weeks doxycycline plus
ivermectin regimens when ivermectin was administered 8
months after doxycycline treatment (Table 6).
Discussion
There is an urgent need for a long-term sterilising or mac-
rofilaricidal drug effective against O. volvulus to comple-
ment ivermectin. In addition, new drugs with modes of
action different to ivermectin must urgently be developed
so that they are available should ivermectin resistance
develop [6], a scenario that may not be too far in the
future [20,21]. Treatment with 6 weeks doxycycline is
effective. While this duration of treatment is considered
Table 2: Geometric means (GM) of mf/mg skin of patients treated with doxycycline only (For significance, see Tables 3 and 4)
Treatment group
Control 2 weeks 4 weeks 6 weeks
Mf-positives/persons examined 14/14 8/8 13/13 3/3
% of mf-positive patients 100 % 100 % 100 % 100 %
GM before treatment 16.7 12.2 10.8 14.1
Percentage of GM 100 % 100 % 100 % 100 %
Mf-positives/persons examined 14/14 7/8 7/13 1/3
% of mf-positive patients 100 % 87.5 % 53.8 % 33.3 %
GM at 18 months * 4.1 4.3 0.7 0.1
% of pre-treatment GM 24.6 % 35.2 % 6.5 % 0.7 %
* = Months after the start of doxycycline treatment.
Table 3: Comparison of significant differences* of skin GM mf of the various treatment regimens 18 months after therapy.
Treatment regimen P-value before treatment P-value 18 months after treatment
Controls vs. 2 weeks 0.1865 0.2262
Controls vs. 4 weeks 0.4146 0.0042
Controls vs. 6 weeks 0.6286 0.0138
2 weeks vs. 4 weeks 0.0577 0.0012
2 weeks vs. 6 weeks 0.1419 0.0028
4 weeks vs. 6 weeks 0.8933 0.5628
* = ANOVA Post Hoc (Bonferroni/Dunn) testFilaria Journal 2006, 5:1 http://www.filariajournal.com/content/5/1/1
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too long for mass treatment [28], shorter regimens are
also preferable for individual treatment and to facilitate
better compliance.
The purpose of this study was to compare different regi-
mens of doxycycline treatment so that we could deter-
mine the minimum effective duration necessary for the
control of onchocerciasis.
Treatment with doxycycline for 2 weeks was not effective
for onchocerciasis control as there was no significant dif-
ference between the untreated control groups and the 2
weeks doxycycline-treated groups 18 months post therapy
(Tables 3 and 4). Treatment with doxycycline for either 4
or 6 weeks on the other hand, had an effect at the same
time point (Tables 3 and 4), which suggests that both the
4 and the 6 week treatment regimens might be equally
effective for onchocerciasis treatment.
One patient treated for 4 weeks with doxycycline plus iver-
mectin a had low mf count (GM = 0.02) (Table 5) in the
skin 12 months after ivermectin treatment, whereas none
of the patients treated for 6 weeks (plus ivermectin) had
any mf. The low numbers of mf left in the skin may be an
indication that either the 4 weeks regimen was not as ben-
eficial as the 6 weeks regimen, or it could be due to the rel-
atively larger sample size of the 4 weeks group (n = 7)
compared to the smaller sample size of the 6 weeks group
(n = 4). This, therefore, calls for a study with a larger sam-
ple size (which is underway) to compare the efficacy of
the 4 and 6 weeks regimens. Nonetheless, what is clear
from this study is that a 2 weeks regimen is not effective
Table 4: Comparison of significant differences* from mf positive/patients examined following the various treatment regimens 18 
months post treatment.
Treatment regimen P-value before treatment P-value 18 months after treatment
Controls vs. 2 weeks > 0.9999 0.3636
Controls vs. 4 weeks > 0.9999 0.0058†
Controls vs. 6 weeks > 0.9999 0.0221†
2 weeks vs. 4 weeks > 0.9999 0.1736
2 weeks vs. 6 weeks > 0.9999 0.1515
4 weeks vs. 6 weeks > 0.9999 > 0.9999
* = Fisher's exact test
† = Significant difference
Table 5: Geometric means (GM) of mf/mg skin of patients treated with doxycycline plus ivermectin*
Treatment group
Ivermectin only 4 weeks doxycycline + ivermectin 6 weeks doxycycline + ivermectin
Mf-positives/persons examined 11/11 7/7 4/4
% of mf-positive patients 100 % 100 % 100 %
GM before doxycycline treatment 11.4 7.6 11.8
% of pre-treatment GM 100 % 100 % 100 %
Mf-positives/persons examined 11/11 7/7 4/4
% of mf-positive patients 100 % 100 % 100 %
GM* when ivermectin was 
administered
6.2 3.8 2.5
% of pre-treatment GM 54.4 % 50.0 % 21.2 %
Mf-positives/persons examined 0/11 0/7 0/4
% of mf-positive patients 0 % 0 % 0 %
GM at 2 months ** 0 0 0
% of pre-treatment GM 0 % 0 % 0 %
Mf-positives/persons examined 8/11 1/7 0/4
% of mf-positive patients 72.7 % 14.3 % 0 %
GM at 12 months ** 1.2 0.02 0
% of pre-treatment GM 10.8 % 0.3 % 0 %
* = Ivermectin was administered 8 months after doxycycline treatment. ** = Months after ivermectin treatment.Filaria Journal 2006, 5:1 http://www.filariajournal.com/content/5/1/1
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for the treatment of onchocerciasis. Four weeks is effective
but may not be as beneficial as the 6 weeks regimen.
The observed reduction of mf in the control groups and
the 2 weeks doxycycline treated patients cannot be fully
explained. However, natural fluctuation unrelated to drug
treatment cannot be ruled out as observed in both veteri-
nary [29] and human studies [30-32]. When the degree of
reduction of mf loads within the same treatment groups
were compared 18 months post therapy using the Wil-
coxon Signed Rank test, there was no significant difference
between the drop of mf loads in the control patients (P=
0.0648) and those observed in the 2 weeks treatment
group (P= 0.1282). In contrast there was a significant dif-
ference in the 4 weeks treatment group (P = 0.0039). Iron-
ically, even though there was more than a 99% reduction
of mf in the 6 weeks treatment group (Table 2), there was
no significant difference when a paired test was performed
using the Wilcoxon Rank test (P= 0.1088). This lack of
impact in the 6 weeks regimen was due to the small sam-
ple size of the group. The significant differences between
the control and the 4 and 6 weeks regimens (Tables 3 and
4) coupled with the clear significant differences between
ivermectin-only treated and 4–6 weeks doxycycline plus
ivermectin groups showed that both the 4 and 6 weeks
doxycycline treatment regimens show a significantly
improved embryostatic effect as compared with the use of
ivermectin alone.
The profound and significant reduction of mf loads pro-
duced by the combined treatment of doxycycline and iver-
mectin is consistent with earlier reports [24,25,27] which
used 100 mg doxycycline per day. This clearly shows that
4–6 weeks treatment with 200 mg doxycycline per day of
patients with moderate to high intensities of O. volvulus
infection is well tolerated and that 18 months post ther-
apy, patients treated for 4–6 weeks had very low mf. Com-
bined treatment of 4 or 6 weeks doxycycline plus
ivermectin both suppressed microfilaridermia in
onchocerciasis patients up to 12 months post therapy.
This suggests an embryostatic effect for doxycycline [27].
This study has shown, that a 4 weeks regimen was effec-
tive, but might not be as beneficial as the 6 weeks regimen.
It is, therefore, recommended that until a clear benefit or
otherwise of a 4 weeks treatment regimen in a larger study
is ascertained, the use of 6 weeks doxycycline treatment
should be further explored for special situations in
onchocerciasis control. As reported earlier [33-35], a sin-
gle controlled application of doxycycline for 6 weeks
accompanied by two additional single doses of ivermectin
in onchocerciasis patients might prove more cost-effective
than annual ivermectin treatment alone in special situa-
tions. One dose should be administered during doxycy-
cline treatment and the other approximately 4–6 months
later to eliminate mf developing in the early weeks of dox-
ycycline treatment. This could reduce the transmission to
a low level if a substantial part of the population in a par-
ticular focus is covered. This combined treatment should
be explored for onchocerciasis control in special condi-
tions, especially as curative treatment for individuals leav-
ing onchocerciasis endemic areas permanently and
wanting to remain free of mf in the long-term, or in areas
where there is apparent existence of sub-optimal efficacy
of ivermectin as reported in some onchocerciasis-endemic
foci in Ghana recently [20,21].
Conclusion
The purpose of this study was to find a shorter possible
regimen that is effective for onchocerciasis treatment with
doxycycline. Treatment for only 2 weeks with 200 mg dox-
ycycline per day was not effective at stoppping microfilar-
iae production. In contrast, both treatments for either 4
weeks or for 6 weeks with 200 mg per day were effective.
The results of this study suggest that the 4 weeks regimen
has the potential to be used for the treatment of onchocer-
ciasis. There was no significant difference between the 4
and 6 weeks regimens, but the reduction in microfilarial
numbers appeared to have been greater after 6 weeks. It is,
therefore, recommended that further studies focus on the
4 weeks regimen, in a larger and preferably, in a double
blind study. Presently, 6 weeks doxycycline treatment can
be recommended for special situations. Since previous
studies have shown that 6 weeks with 100 mg doxycycline
Table 6: Comparison of significant differences between the treatment regimens 12 months post ivermectin (20 months after 
doxycycline) treatment.
Treatment regimen Geometric mean* Mf positive/persons examined‡
P value before treatment P value after treatment P value before treatment P value after treatment
Controls vs. 4 weeks 0.8265 0.0056 >0.9999 0.0498
Controls vs. 6 weeks 0.6138 0.0095 >0.9999 0.0256
4 weeks vs. 6 weeks 0.7623 0.2337 >0.9999 >0.9999
* = ANOVA Post Hoc (Bonferroni/Dunn) test
‡ = Fisher's exact testFilaria Journal 2006, 5:1 http://www.filariajournal.com/content/5/1/1
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per day are effective at stopping microfilariae production,
this dose may be sufficient.
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